Lonza Group Investor Relations Material
Latest events
H1 2025
Lonza Group
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lonza Group AG
Access all reports
Lonza Group AG offers contract development and manufacturing services to the pharmaceutical, biotechnology, and specialty ingredients markets. The company supports drug production across biologics, small molecules, and cell and gene therapy, along with nutrition and personal care ingredients. It operates manufacturing and research facilities globally. The company is headquartered in Basel, Switzerland, and its shares are listed on the SIX.
Key slides for Lonza Group AG
H2 2024
Lonza Group AG
H2 2024
Lonza Group AG
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
LONN
Country
🇨🇭 Switzerland